Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michael Cecchini
EGFRExon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed byT790M-Mediated Resistance
Journal of the National Comprehensive Cancer Network : JNCCN
Medicine
Oncology
Related publications
Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.13-19 Surgery for cIIIB Lung Adenocarcinoma After Response to Erlotinib, Survival and Management of Postoperative Oligoprogressions
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients With Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
Clinical Cancer Research
Cancer Research
Oncology
Reply To: Relationship Between LAT1 Expression and Resistance to Chemotherapy in Pancreatic Ductal Adenocarcinoma
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Prolonged Response to First-Line Erlotinib for Advanced Lung Adenocarcinoma
Journal of Experimental and Clinical Cancer Research
Cancer Research
Oncology
Image-Based Detection and Targeting of Therapy Resistance in Pancreatic Adenocarcinoma
Nature
Multidisciplinary
Pancreatic Adenocarcinoma
Induction of ADAM10 Drives Fibrosis and Therapeutic Resistance in Response to SBRT in Pancreatic Ductal Adenocarcinoma
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
P3.03-12 Cyclic Mechanical Strain and Myoferlin Modulates Lung Adenocarcinoma Cell Proliferation and Erlotinib Resistance
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
